Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer

Table 3 Studies that have assessed the role of a PET scan in the response prediction of patients with neoadjuvant treated Barrett’s cancer and cancer of the gastroesophageal junction

Author	n	CTx	2nd PET	Correlation of PET with histopathological response yes/no
Lordick et al[60], 2007	110	Cis/5-FU	2 wk during CTx	Yes
Ott et al[59], 2006	65	Cis/5-FU	2 wk during CTx	Yes
Gillham et al[49], 2006	29	Cis/5-FU	After CTx	No
Levine et al[61], 2006	52	Cis/5-FU	After CTx	Yes
Swisher et al[62], 2004	73	Cis/5-FU/50,4 Gy	After RCTx	Yes
		Irin/5-FU/Taxol/50,4 Gy
		Taxol/Carbo/50,4 Gy
Brink et al[63], 2004	13	Cis/5-FU	After CTx	No
Arslan et al[64], 2002	22	Cis/Taxol/50,4 Gy	After RCTx	Yes
Weber et al[65], 2001	40	Cis/5-FU	2 wk during CTx	Yes

Cis: Cisplatin; Irin: Irinotecan; Carbo: Carboplatin; 5-FU: 5 Flurouracil; Gy: Gray; RCTx: Radiochemotherapy; CTx: Chemotherapy.